Hutchmed (China) vs Zoetis
Hutchmed (China) (HCM) and Zoetis (ZTS) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- —
- Last close
- $13.22
- 12 months
- −6.8%
- Market value
- $32.9B
- Last close
- $79.11
- 12 months
- −31.7%
At a glance
- The biggest part of Hutchmed (China)'s revenue is Oncology/Immunology (52%); at Zoetis it is Vaccines (21%).
- Over the last 12 months Hutchmed (China)'s share price moved −6.8% and Zoetis's −31.7%; against the S&P 500 that is −12.5 points and −37.5 points.
- In their last fiscal years Hutchmed (China) kept 83.3% of revenue as net income and Zoetis 28.2%.
- In the last 90 days insiders reported 0 open-market purchases at Hutchmed (China) and 0 at Zoetis; members of Congress disclosed 0 trades in Hutchmed (China) and 4 in Zoetis.
- Next results: Hutchmed (China) not announced, Zoetis Feb 10, 2027.
How each one makes money: Hutchmed (China) revenue · Zoetis revenue
Share prices on one chart
Hutchmed (China) and Zoetis, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Hutchmed (China) HCMNASDAQ · Pharmaceutical Preparations | Zoetis ZTSNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | — | $32.9B |
| Revenue, last fiscal year | $549M | $9.47B |
| Net income, last fiscal year | $457M | $2.67B |
| Net marginNet income as a share of revenue | 83.3% | 28.2% |
| Free cash flow | −$78.8M | $2.28B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Zoetis against
Common questions
How is Hutchmed (China) different from Zoetis?
Hutchmed (China) (HCM) is in Pharmaceutical Preparations on NASDAQ, with $549M of revenue in its last fiscal year and a net margin of 83.3%. Zoetis (ZTS) is in Pharmaceuticals on NYSE, with $9.47B of revenue in its last fiscal year and a net margin of 28.2%. The biggest part of Hutchmed (China)'s revenue is Oncology/Immunology (52%); at Zoetis it is Vaccines (21%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Hutchmed (China) and Zoetis compare in size?
OQRO does not hold a reliable market value for both companies, so this page does not compare their size.
Whose share price rose more over the last 12 months, HCM or ZTS?
Over the last 12 months Hutchmed (China) moved −6.8% and Zoetis −31.7%. Past price moves say nothing about the future.
Which has had more insider buying, Hutchmed (China) or Zoetis?
Since 2006, Zoetis insiders reported 25 open-market purchases against 0 for Hutchmed (China). These are counts of what was filed, not a view on either stock.
Do members of Congress trade HCM or ZTS?
In the last 12 months, members of Congress disclosed 0 trades in Hutchmed (China) (HCM) and 14 in Zoetis (ZTS).
When did insiders last buy HCM and ZTS?
Hutchmed (China): no open-market purchase on record. Zoetis: May 13, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Hutchmed (China) pageZoetis pageRare insider trades this weekAll comparisons
https://oqro.io/compare/hcm-vs-zts






